Tricida to Provide an End-of-Year Business Update

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) announced it will provide a business update on its investigational drug veverimer (TRC101), aimed at treating metabolic acidosis in chronic kidney disease (CKD) patients. The update will cover development, regulatory status, and patent protection. A conference call is scheduled for December 8, 2020, at 4:30 PM ET, which will be accessible via webcast and dial-in. Veverimer is designed to address metabolic acidosis, a common complication in CKD affecting approximately three million patients in the U.S.

Positive

• Tricida will provide an update on veverimer's development and regulatory status, indicating ongoing progress.
• The drug targets metabolic acidosis in CKD, which affects a significant patient population, suggesting potentially meaningful market demand.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will provide an end-of-year business update on veverimer’s development program, regulatory status and patent protection.

Tricida will host a conference call and webcast at 4:30 pm Eastern Time on December 8, 2020. The webcast, including slides, or conference call may be accessed as follows:

Tricida Update End-of-Year Business Update Conference Call
Tuesday, December 8, 2020 4:30 pm Eastern Time
Webcast:	IR.Tricida.com
Dial-in:	(877) 377-5478
International:	(629) 228-0740
Conference ID:	2669339

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.tricida.com.

Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of
Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

What is Tricida's upcoming business update about veverimer (TCDA)?

Tricida will discuss veverimer's development program, regulatory status, and patent protection in a conference call on December 8, 2020.

When is the Tricida conference call scheduled?

The conference call is scheduled for December 8, 2020, at 4:30 PM ET.

How can I access Tricida's conference call on December 8, 2020?

The conference call can be accessed via webcast at IR.Tricida.com or by dialing (877) 377-5478.

What condition does veverimer (TCDA) aim to treat?

Veverimer is designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).

How many patients in the U.S. are affected by CKD and may benefit from veverimer?

Approximately three million patients in the U.S. are estimated to be at risk due to CKD-related metabolic acidosis.